Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials

Autor: Martín, M., Loibl, S., Hyslop, T., De la Haba-Rodríguez, J., Aktas, B., Cirrincione, C.T., Mehta, K., Barry, W.T., Morales, S., Carey, L.A., Garcia-Saenz, J.A., Partridge, A., Martinez-Jañez, N., Hahn, O., Winer, E., Guerrero-Zotano, A., Hudis, C., Casas, M., Rodriguez-Martin, C., Furlanetto, J., Carrasco, E., Dickler, M.N.
Zdroj: In European Journal of Cancer August 2019 117:91-98
Databáze: ScienceDirect
Externí odkaz: